Mechanistically, DAB2IP acts as a scaffold to assemble a ternary complex with PARP-1 and E3 ubiquitin ligases, facilitating PARP-1 ubiquitination and proteasomal degradation, offering a new targeting strategy to enhance radiotherapy efficacy in RCC [95]. Here, PARP1 is linked to renal cell carcinoma.